Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis
- PMID: 16492715
- PMCID: PMC1860046
- DOI: 10.1136/gut.2005.081059
Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis
Abstract
Background and aims: Portal hypertension in cirrhosis is mediated in part by increased intrahepatic resistance, reflecting an increased sensitivity of the hepatic microvasculature to vasoconstrictors. Activation of the RhoA/Rho-kinase pathway is essential for contraction of vascular smooth muscle. The aim of this study was to investigate RhoA/Rho-kinase mediated regulation of the intrahepatic vascular tone in cirrhotic rats.
Methods: Cirrhosis was induced by bile duct ligation (BDL). Hepatic RhoA and Rho-kinase expressions were studied by real time reverse transcription polymerase chain reaction and western blot analysis. Hepatic Rho-kinase activity in rat and human livers was assessed as phosphorylation of the Rho-kinase substrate moesin. The effect of the Rho-kinase inhibitor Y-27632 on hepatic perfusion pressure was measured in livers perfused at constant flow. The in vivo effect of intravenous application of Y-27632 was studied by haemodynamic measurements.
Results: Hepatic expressions of RhoA and Rho-kinase were increased at mRNA and protein level in BDL rats. Intrahepatic moesin phosphorylation was increased in livers from cirrhotic rats and patients with alcohol induced cirrhosis. Y-27632 reduced the basal perfusion pressure of in situ perfused livers in BDL rats but not in sham operated rats. Y-27632 reduced the sensitivity to methoxamine in isolated perfused livers in sham operated rats more than in BDL rats. In vivo, Y-27632 reduced portal pressure to a greater extent in BDL rats than in sham operated rats. Intrahepatic vascular resistance was decreased in response to bolus injection of Y-27632 in BDL rats but not in sham operated rats.
Conclusions: Upregulation of RhoA and Rho-kinase contributes to increased intrahepatic resistance in cirrhotic rats and to an increased sensitivity of cirrhotic livers to vasoconstrictors.
Conflict of interest statement
Conflict of interest: None declared.
Similar articles
-
Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats.Gastroenterology. 2006 Mar;130(3):838-54. doi: 10.1053/j.gastro.2005.11.029. Gastroenterology. 2006. PMID: 16530523
-
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.Hepatology. 2007 Jul;46(1):242-53. doi: 10.1002/hep.21673. Hepatology. 2007. PMID: 17596891
-
Amiloride reduces portal hypertension in rat liver cirrhosis.Gut. 2010 Jun;59(6):827-36. doi: 10.1136/gut.2009.197756. Gut. 2010. PMID: 20551467
-
Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension.Adv Exp Med Biol. 2003;543:127-37. Adv Exp Med Biol. 2003. PMID: 14713118 Review.
-
Recent evidence for an involvement of rho-kinase in cerebral vascular disease.Stroke. 2006 Aug;37(8):2174-80. doi: 10.1161/01.STR.0000231647.41578.df. Epub 2006 Jun 29. Stroke. 2006. PMID: 16809566 Review.
Cited by
-
Spironolactone lowers portal hypertension by inhibiting liver fibrosis, ROCK-2 activity and activating NO/PKG pathway in the bile-duct-ligated rat.PLoS One. 2012;7(3):e34230. doi: 10.1371/journal.pone.0034230. Epub 2012 Mar 30. PLoS One. 2012. PMID: 22479572 Free PMC article.
-
Reactive oxygen species are involved in regulating hypocontractility of mesenteric artery to norepinephrine in cirrhotic rats with portal hypertension.Int J Biol Sci. 2014 Mar 15;10(4):386-95. doi: 10.7150/ijbs.8081. eCollection 2014. Int J Biol Sci. 2014. PMID: 24719556 Free PMC article.
-
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.Br J Pharmacol. 2009 May;157(2):258-70. doi: 10.1111/j.1476-5381.2009.00158.x. Epub 2009 Mar 26. Br J Pharmacol. 2009. PMID: 19338580 Free PMC article.
-
Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.World J Gastroenterol. 2016 May 14;22(18):4484-500. doi: 10.3748/wjg.v22.i18.4484. World J Gastroenterol. 2016. PMID: 27182159 Free PMC article.
-
Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.Pharm Res. 2011 Aug;28(8):2045-54. doi: 10.1007/s11095-011-0430-9. Epub 2011 Mar 26. Pharm Res. 2011. PMID: 21442374 Free PMC article.
References
-
- Hernandez‐Guerra M, Garcia‐Pagan J C, Bosch J. Increased hepatic resistance. A new target in the pharmacological therapy of portal hypertension. J Clin Gastroenterol 200539S131–S137. - PubMed
-
- Menon K V N, Kamath P S. Regional and systemic hemodynamic disturbances in cirrhosis. Clin Liver Dis 20015617–627. - PubMed
-
- Groszmann R J, Abraldes J G. Portal hypertension. From bench to bedside. J Clin Gastroenterol 200539S125–S130. - PubMed
-
- Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 20015629–644. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials